DexCom, Inc.

$81,05$1,64 (+2,07 %)
Last updated on --.

DexCom, Inc. price

24 Hours+2,07 %+$1,640
30 days−5,67 %-$4,870
60 days−2,38 %-$1,980
90 days−10,74 %-$9,750

About DexCom, Inc.

DexCom, Inc. er et medisinsk teknologiselskap som primært fokuserer på å innovere, utvikle og markedsføre kontinuerlige glukoseovervåkingssystemer (CGM). Selskapet opererer i USA og internasjonalt, og tilbyr løsninger for både personer som håndterer diabetes og helsepersonell. Produktporteføljen inkluderer DexCom G6, et omfattende CGM-system for diabetesbehandling; Dexcom Real-Time API, som gjør det mulig for autoriserte tredjepartsutviklere å integrere live CGM-data i sine digitale helseapplikasjoner; Dexcom ONE, som har som mål å erstatte tradisjonell fingerstikkblodsukker-testing for behandlingsbeslutninger; og Dexcom Share, en plattform for fjernovervåking. Selskapet utvikler også Dexcom G7, sin neste generasjons CGM-system. Videre har DexCom, Inc. en lisens- og samarbeidsavtale med Verily Life Sciences LLC og Verily Ireland Limited for å fremme produkter for blod- eller interstitiell glukoseovervåking. Selskapet selger sine produkter direkte til spesialister som endokrinologer, leger og diabetespedagoger. DexCom, Inc. ble grunnlagt i 1999 og har sitt hovedkontor i San Diego, California.

Aksjesymbol
DXCM
Selskap
DexCom, Inc.
Industri
Helsevesenet
Kategori
US
Aksjesplitt / omvendt splitt
14
Lanseringsdato
14. apr. 2005
Notert børs
NASDAQ

Finansielle forhold

Q3 FY2026 Resultater
Rapportperiode: 1. juli 2026 – 30. sep. 2026

Sammendrag: DXCM reported Revenue of 1.34B (+11,18 %), beating expectations; EPS of 0,73 (+19,67 %), beating expectations.

Inntekt (USD)Slå1,34 mrd.+11,18 %1,33 mrd.+12,25 %15,66 mill.+1,17 %
EPS (USD)Slå0,73+19,67 %0,68+17,18 %0,06+8,14 %
Finansielle estimater
● Faktisk● Estimere
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
0,700,680,510,640,72
+105,88 %+78,94 %+88,88 %+42,22 %+2,85 %
● EPS● YoY
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
7,50 mrd.6,34 mrd.6,63 mrd.6,46 mrd.6,24 mrd.
4,77 mrd.3,59 mrd.3,68 mrd.3,83 mrd.3,70 mrd.
63,65 %56,68 %55,42 %59,39 %59,36 %
● Eiendeler● Forpliktelser● Forhold
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
659,90 mill.294,00 mill.525,60 mill.269,20 mill.325,60 mill.
+230,77 %−2,46 %+185,96 %−11,16 %−50,66 %
● CFO● YoY

Aksjonærer

Aksjonærer
BLACKROCK, INC.9,96 %
VANGUARD CAPITAL MANAGEMENT LLC6,57 %
VANGUARD PORTFOLIO MANAGEMENT LLC5,12 %
STATE STREET CORP4,77 %
INVESCO LTD.3,98 %
Andre69,58 %
Institusjoner
% Eiet101,12 %+5,99 %
Aksjer holdt389,42 mill.+23,07 mill.
Institusjoner1 024+13
% EietPris
Navn% EietEndre
BLACKROCK, INC.9,96 %−-720,23k
VANGUARD CAPITAL MANAGEMENT LLC6,57 %+188,79k
VANGUARD PORTFOLIO MANAGEMENT LLC5,12 %+436,59k
STATE STREET CORP4,77 %+445,96k
INVESCO LTD.3,98 %+7,21 mill.

Utbytte

Aksjesplittelser
Lanseringsdato: 14. apr. 2005
DatoForhold
13. juni 20221 → 4

DexCom, Inc. conversion tables

DXCMDXCM
USDUSD
0.5 DXCM40,52 USD
1 DXCM81,05 USD
5 DXCM405,25 USD
10 DXCM810,5 USD
USDUSD
DXCMDXCM
0.5 USD0,006169 DXCM
1 USD0,012338 DXCM
5 USD0,06169 DXCM
10 USD0,12338 DXCM

More to explore

FAQ

DXCM is trading at $81,05, +2,07 % over the last 24 hours. Track live moves on the price chart at the top of this page.

The DXCM stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. DXCM is currently trading at $81,05, +2,07 % over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on DXCM price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Helsevesenet sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. DXCM's P/E ratio is currently 31,57 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from DXCM; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against DXCM's historical range and other companies in the Helsevesenet sector.

DexCom, Inc.'s market cap is currently 30,02 mrd. USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.